The efficacy of ascofuranone in a consecutive treatment on Trypanosoma brucei brucei in mice

Parasitology International

Volumn 52, Issue 2, 2003, Pages 155-164

  Yabu, Yoshisada ^a   Yoshida, Ayako ^a,f   Suzuki, Takashi ^a   Nihei, Coh Ichi ^b   Kawai, Keisuke ^b   Minagawa, Nobuko ^c   Hosokawa, Tomoyoshi ^d   Nagai, Kazuo ^e   Kita, Kiyoshi ^b   Ohta, Nobuo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^d Applied Biological Institute   (Japan)

^e CHUBU UNIVERSITY   (Japan)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ascofuranone; Chemotherapy; Consecutive treatment; Intraperitoneal; Mouse; Oral; Trypanosoma brucei brucei

Indexed keywords

ANTITRYPANOSOMAL AGENT; ASCOFURANONE; GLYCEROL; OXIDOREDUCTASE; UBIQUINOL OXIDASE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CHEMOTHERAPY; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; MORPHOLOGY; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; TREATMENT OUTCOME; TRYPANOSOMA BRUCEI; TRYPANOSOMIASIS;

TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA BRUCEI BRUCEI;

EID: 0037866531     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5769(03)00012-6     Document Type: Article

References (45)

1. Bales J.D., Harrison S.M., Mbwabi D.L., Schechter P.J. Treatment of arsenical refractory Rhodesian sleeping sickness in Kenya. Ann Trop Med Parasitol. 83:(1):1989;111-114.
2. Bacchi C.J., Nathan H.C., Livingston T., Valladares G., Saric M., Sayer P.D., et al. Differential susceptibility to DL-α-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense. Antimicrob Agents Chemother. 34:1990;1183-1188.
3. Kuzoe FAS. Current situation of African trypanosomiasis. Acta Trop. 54:1993;153-162.
4. Wang C.C. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol. 35:1995;93-127.
5. Iten M., Matovu E., Brun R., Kaminsky R. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-α-difluoromethylornithine (DFMO). Trop Med Parasitol. 46:1995;190-194.
6. Keiser J., Stich A., Burri C. New drugs for the treatment of human African trypanosomiasis: research and development. Trends Parasitol. 17:2001;42-49.
7. Sasaki H., Hosokawa T., Sawada M., Ando K. Isolation and structure of ascofuranone and ascofuranol, antibiotics with hypolipidemic activity. J Antibiot. 26:1973;676-680.
8. Magae J., Hosokawa T., Ando K., Nagai K., Tamura G. Antitumor protective property of an isoprenoid antibiotic, ascofuranone. J Antibiot. 35:1982;1547-1552.
9. Magae J., Nagai K., Ando K., Yamasaki M., Tamura G. Effects of an antitumor agent, ascofuranone, on the macromolecular syntheses of intact cells. J Antibiot. 36:1983;892-899.
10. Magae J., Hotta M., Nagai K., Suzuki S., Ando K., Yamasaki M., et al. Activation of natural cytotoxic activity and concomitant reduction of triglyceride content of murine spleen, treated with an antitumor antibiotic, ascofuranone. J Antibiot. 39:1986;676-681.
11. Magae J., Suzuki S., Nagai K., Yamasaki M., Ando K., Tamura G. In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system. Cancer Res. 46:1986;1073-1078.
12. Magae J., Hosokawa T., Matsuda Y., Hotta M., Hayasaki J., Nagai K., et al. Suppression of hypertriglyceridemia of Ehrlich carcinoma-bearing mice by an antibiotic, ascofuranone. Cancer Res. 47:1987;96-99.
13. Magae J., Nagai K., Suzuki S., Yamasaki M., Ando K., Tamura G. Macrophage-specific effect on lipid metabolism by an antibiotic, ascofuranone. J Antibiot. 40:1987;202-208.
14. Magae J., Hayasaki J., Matsuda Y., Hotta M., Hosokawa T., Suzuki S., et al. Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes. J Antibiot. 41:1988;959-965.
15. Magae J., Nagai K., Ando K., Tamura G. Differentiation of mouse and human myeloid leukemia cells induced by an antitumor antibiotic, ascofuranone. Agric Biol Chem. 52:1988;3143-3147.
16. Minagawa N., Yabu Y., Kita K., Nagai K., Ohta N., Meguro K., et al. An antibiotic, ascofuranone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei. Mol Biochem Parasitol. 81:1996;127-136.
17. Clarkson A.B. Jr, Brohn F.H. Trypanosomiasis: an approach to chemotherapy by the inhibition of carbohydrate catabolism. Science. 194:1976;204-206.
18. van der Meer C., Versluijs-Broers J.A.M., Opperdoes F.R. Trypanosoma brucei: trypanocidal effect of salicylhydroxamic acid plus glycerol in infected rats. Exp Parasitol. 48:1979;126-134.
19. Clarkson A.B. Jr, Grady R.W., Grossman S.A., McCallum R.J., Brohn F.H. Trypanosoma brucei brucei: a systematic screening for alternatives to the salicylhydroxamic acid-glycerol combination. Mol Biochem Parasitol. 3:1981;271-291.
20. Grady R.W., Bienen E.J., Clarkson A.B. Jr. Esters of 3,4-dihydroxybenzoic acid, highly effective inhibitors of the sn-glycerol-3-phosphate oxidase of Trypanosoma brucei brucei. Mol Biochem Parasitol. 21:1986;55-63.
21. Grady R.W., Bienen E.J., Clarkson A.B. Jr. p-Alkyloxybenzhydroxamic acids, effective inhibitors of the trypanosome glycerol-3-phosphate oxidase. Mol Biochem Parasitol. 19:1986;231-240.
22. Clarkson A.B. Jr, Bienen E.J., Pollakis G., Grady R.W. Trypanocidal CoQ analogs: their effect on other mitochondrial systems. Comp Biochem Physiol. 94B:1989;245-251.
23. Clarkson AB Jr, Bienen EJ, Pollakis G, Saric M, McIntosh L, Grady RW, Trypanosome alternative oxidase. In Chemotherapy for trypanosomiasis. Proceedings of a workshop held at ILRAD, Nairobi, Kenya, 1989: pp. 43-48.
24. Clarkson A.B. Jr, Bienen E.J., Pollakis G., Grady R.W. Respiration of bloodstream forms of the parasite Trypanosoma brucei brucei is dependent on a plant-like alternative oxidase. J Biol Chem. 264:1989;17770-17776.
25. Bienen E.J., Saric M., Pollakis G., Grady R.W., Clarkson A.B. Jr. Mitochondrial development in Trypanosoma brucei brucei transitional bloodstream forms. Mol Biochem Parasitol. 45:1991;185-192.
26. Kornblatt J.A., Nthale J., McOdimba F. Purification of sn-glycerol-3-phosphate dehydrogenase from Trypanosoma brucei brucei. Biochem Cell Biol. 70:1992;136-141.
27. Grady R.W., Bienen E.J., Dieck H.A., Saric M., Clarkson A.B. Jr. N-n-Alkyl-3,4-dihydroxybenzamides as inhibitors of the trypanosome alternative oxidase: activity in vitro and in vivo. Antimicrob Agents Chemother. 37:1993;1082-1085.
28. Hannaert V., Michels PAM. Structure, function, and biogenesis of glycosomes in kinetoplastida. J Bioenerg Biomembr. 26:1994;205-212.
29. Priest J.W., Hajduk S.L. Developmental regulation of mitochondrial biogenesis in Trypanosoma brucei. J Bioenerg Biomembr. 26:1994;179-191.
30. Chaudhuri M., Ajayi W., Temple S., Hill G.C. Identification and partial purification of a stage-specific 33 kDa mitochondrial protein as the alternative oxidase of the Trypanosoma brucei brucei bloodstream trypomastigotes. J Eukaryot Microbiol. 42:1995;467-472.
31. Chaudhuri M., Hill G.C. Cloning, sequencing, and functional activity of the Trypanosoma brucei brucei alternative oxidase. Mol Biochem Parasitol. 83:1996;125-129.
32. Fukai Y., Nihei C., Yabu Y., Suzuki T., Ohta N., Minagawa N., et al. Strain-specific difference in amino acid sequences of trypanosome alternative oxidase. Parasitol Int. 51:2002;195-199.
33. Nihei C., Fukai Y., Kita K. Trypanosome alternative oxidase as a target of chemotherapy. Biochim Biophys Acta. 1587:2002;234-239.
34. Yabu Y., Minagawa N., Kita K., Nagai K., Honma M., Sakajo S., et al. Oral and intraperitoneal treatment of Trypanosoma brucei brucei with a combination of ascofuranone and glycerol in mice. Parasitol Int. 47:1998;131-137.
35. Yabu Y. An axenic culture system for the transformation of bloodstream forms to procyclic forms of Trypanosoma brucei brucei in vitro. Southeast Asian J Trop Med Public Health. 24:1993;706-711.
36. Zhang Z.Q., Giroud C., Baltz T. In vivo and in vitro sensitivity of Trypanosoma evansi and T. equiperdum to diminazene, suramin, Melcy, quinapyramine and isometamidium. Acta Trop. 50:1991;101-110.
37. Lanham S.M., Godfrey D.G. Isolation of salivarian trypanosome from man and other mammals using DEAE-cellulose. Exp Parasitol. 28:1970;521-534.
38. Kita K., Konishi K., Anraku Y. Terminal oxidases of Escherichia coli aerobic respiratory chain. I. purification and properties of cytochrome b562-o complex from cells in the early exponential phase of aerobic growth. J Biol Chem. 259:1984;3368-3374.
39. Fukai Y., Amino H., Hirawake H., Yabu Y., Ohta N., Minagawa N., et al. Functional expression of the ascofuranone-sensitive Trypanosoma brucei brucei alternative oxidase in the cytoplasmic membrane of Escherichia coli. Comp Biochem Physiol C. 124:1999;141-148.
40. Reuner B., Vassella E., Yutzy B., Boshart M. Cell density triggers slender to stumpy differentiation of Trypanosoma brucei bloodstream forms in culture. Mol Biochem Parasitol. 90:1997;269-280.
41. van Deursen F.J., Shahi S.K., Turner C.M., Hartmann C., Guerra-Giraldez C., Matthews K.R., et al. Characterisation of the growth and differentiation in vivo and in vitro - of bloodstream - forms Trypanosoma brucei strain TREU 927. Mol Biochem Parasitol. 112:2001;163-171.
42. Giffin B.F., McCann P.P., Bitonti A.J., Bacchi C.J. Polyamine depletion following exposure to DL-α-difluorometylornithine both in vivo and in vitro initiates morphological alternations and mitochondrial activation in a monomorphic strain of Trypanosoma brucei brucei. J Protozool. 33:1986;238-243.
43. McCann P.P., Bacchi C.J., Clarkson A.B., Bey P., Sjoerdsma A., Schecter P.J., et al. Inhibition of polyamine biosynthesis by alpha-difluotomethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects. Am J Trop Med Hyg. 35:1986;1153-1156.
44. Giffin B.F., McCann P.P. Physiological activation of the mitochondrion and the transformation capacity of DFMO induced intermediate and short stumpy bloodstream form trypanosomes. Am J Trop Med Hyg. 40:1989;487-493.
45. 2+ during differentiation of bloodstream stages in vitro. Exp Parasitol. 83:1996;134-146.